Expression of Stanniocalcin 2 in Breast Cancer and Its Clinical Significance

Abstract

This study aims to explore the expression of stanniocalcin 2 (STC2) gene in breast cancer and its clinical significance. Female patients with breast cancer from Zhongnan Hospital of Wuhan University admitted during March 2014 to October 2014 were enrolled in this study. All the tissues used in this experiment included 50 cases of breast cancer tissues and corresponding 50 cases of paracancer normal breast tissues with complete patients’ information. The real-time quantitative polymerase chain reaction (qPCR) was applied to detect the expression of STC2 gene in 50 cases of breast cancer and paracancer normal breast tissues. The results showed that the expression level of STC2 gene in 50 cases of breast cancer tissues was significantly higher than that in paracancer normal breast tissues (P<0.001). The expression of STC2 gene was correlated with lymph node metastasis, distant metastasis, TNM stage and histological grade (P<0.001). The expression level of STC2 gene was significantly higher in breast cancer tissues with higher expression of Ki-67 (P<0.001). The expression level of STC2 gene was significantly higher in estrogen receptor (ER) positive breast cancer tissues than in ER negative ones (P<0.001). However, different groups of age, pathological type, tumor size, PR expression and human epidermal growth factor receptor-2 (HER2) expression did not show significant differences in STC2 expression (P>0.05). In conclusion, the abnormal overexpression of STC2 gene may play a role in the development and progression of breast cancer, and it can be used as an independent metastasis and prognostic factor of breast cancer. In addition, STC2 gene probably promotes the development and metastasis of breast cancer by interacting with estrogen and ER, and it may become a new direction for breast cancer endocrine therapy.

Keywords

stanniocalcin 2 / breast cancer / real-time quantitative polymerase chain reaction / metastasis

References

[1] TorreLA, BrayF, SiegelRL, et al.. Global cancer statistics, 2012. CA Cancer J Clin, 2015, 65(2): 87-108

[2] SiegelRL, MillerKD, JemalA, et al.. Cancer Statistics, 2019. CA Cancer J Clin, 2019, 69(1): 7-34

[3] ChangAC, JellinekDA, ReddelRR. Mammalian stanniocalcins and cancer. Endocr Relat Cancer, 2003, 10(3): 359-373

[4] ChangAC, JanosiJ, HulsbeekM, et al.. A novel human cDNA highly homologous to the fish hormone stanniocalcin. Mol Cell Endocrinol, 1995, 112(2): 241-247

[5] LinS, GuoQ, WenJ, et al.. Survival analyses correlate stanniocalcin 2 overexpression to poor prognosis of nasopharyngeal carcinomas. J Exp Clin Cancer Res, 2014, 33: 26

[6] ZhangZH, WuYG, QinCK, et al.. Stanniocalcin 2 expression predicts poor prognosis of hepatocellular carcinoma. Oncol Lett, 2014, 8(5): 2160-2164

[7] YokoboriT, MimoriK, IshiiH, et al.. Clinical significance of stanniocalcin 2 as a prognostic marker in gastric cancer. Ann Surg Oncol, 2010, 17(10): 2601-2607

[8] GirgisAH, IakovlevVV, BeheshtiB, et al.. Multilevel whole-genome analysis reveals candidate biomarkers in clear cell renal cell carcinoma. Cancer Res, 2012, 72(20): 5273-5284

[9] RadonićA, ThulkeS, MackayIM, et al.. Guideline to reference gene selection for quantitative real-time PCR. Biochem Biophys Res Commun, 2004, 313(4): 856-862

[10] YeungBH, LawAY, WongCK. Evolution and roles of stanniocalcin. Mol Cell Endocrinol, 2012, 349(2): 272-280

[11] ChuSJ, ZhangJ, ZhangR, et al.. Evolution and functions of stanniocalcins in cancer. Int J Immunopathol Pharmacol, 2015, 28(1): 14-20

[12] YangQ, FengM, MaX, et al.. Gene expression profile comparison between colorectal cancer and adjacent normal tissues. Oncol Lett, 2017, 14(5): 6071-6078

[13] La VerdeN, BiagioliE, GerardiC, et al.. Role of patient and tumor characteristics in sentinel lymph node metastasis in patients with luminal early breast cancer: an observational study. Springerplus, 2016, 5: 114

[14] KastK, LinkT, FriedrichK, et al.. Impact of breast cancer subtypes and patterns of metastasis on outcome. Breast Cancer Res Treat, 2015, 150(3): 621-629

[15] KimbungS, LomanN, HedenfalkI. Clinical and molecular complexity of breast cancer metastases. Semin Cancer Biol, 2015, 35: 85-95

[16] BandalaC, De la Garza-MontanoP, Cortes-AlgaraA, et al.. Association of Histopathological Markers with Clinico-Pathological Factors in Mexican Women with Breast Cancer. Asian Pac J Cancer Prev, 2015, 16(18): 8397-8403

[17] PratA, CheangMC, MartínM, et al.. Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer. J Clin Oncol, 2013, 31(2): 203-209

[18] PoschnerS, Maier-SalamonA, ThalhammerT, et al.. Resveratrol and other dietary polyphenols are inhibitors of estrogen metabolism in human breast cancer cells. J Steroid Biochem Mol Biol, 2019, 190: 11-18

[19] MiyoshiY, ShienT, OgiyaA, et al.. Associations in tumor infiltrating lymphocytes between clinicopathological factors and clinical outcomes in estrogen receptor-positive/human epidermal growth factor receptor type 2 negative breast cancer. Oncol Lett, 2019, 17(2): 2177-2186

[20] HiltonHN, ClarkeCL, GrahamJD. Estrogen and progesterone signalling in the normal breast and its implications for cancer development. Mol Cell Endocrinol, 2018, 5(466): 2-14

[21] MasihS. Tree-based machine learning algorithms identified minimal set of miRNA biomarkers for breast cancer diagnosis and molecular subtyping. Gene, 2018, 677: 111-118

[22] GaoJJ, SwainSM. Luminal A Breast Cancer and Molecular Assays: A Review. Oncologist, 2018, 23(5): 556-565